Pelthos Therapeutics acquired Xeglyze®, an FDA-approved prescription medication for head lice infestation.
The acquisition adds a complementary asset to Pelthos's commercial portfolio.
Xeglyze is a pediculicide indicated for the topical treatment of head lice infestation in patients 6 months of age and older.
Acquisition Details
Pelthos acquired Xeglyze from Hatchtech Pty Ltd. for $1.8 million with no future milestone payments.
Product Features
Xeglyze is highly differentiated with ovicidal and lousicidal activity, offering a more effective treatment in a single 10-minute application.
Commercialization Strategy
Pelthos plans to relaunch Xeglyze in the first half of 2027, aligning with their goal of addressing unmet patient needs.
- Head lice infestation affects millions of children in the U.S. annually, highlighting the market potential for Xeglyze.
- Xeglyze's unique features, like its ovicidal and lousicidal activity, address common drawbacks of existing head lice treatments.
The acquisition of Xeglyze strengthens Pelthos's product portfolio, aligns with their patient-centric approach, and signifies a strategic investment in innovative therapies.